Tectonic Therapeutic

TECX Rare disease Lead: Phase 2 4 Biotech Distilled articles ↓

Most recent annual filing: 2026-02-26

Catalyst timeline

AZD5462 AstraZeneca Ph2b readout2H 2026AZD5462 AstraZeneca Ph2b readout, 2H 2026, notable
TX45 toplineearly 1Q 2027TX45 topline, early 1Q 2027, thesis-defining
TX45 readout1Q 2027TX45 readout, 1Q 2027, material
TX2100 Ph2 startearly 2027TX2100 Ph2 start, early 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

TX45

Protein Target: RXFP1

Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction Phase 2 subcutaneous
Pulmonary Hypertension Associated with Interstitial Lung Disease Phase 2 subcutaneous

TX2100

Protein Target: APJ, APLNR, apelin receptor, APJ receptor

Hereditary Hemorrhagic Telangiectasia Phase 1 subcutaneous

Technology platforms

GEODe

GPCRs Engineered for Optimal Discovery — proprietary yeast display platform for discovering biologic drugs (antibodies, Fab, VHH) targeted to GPCRs; enables stabilization of pharmacologically relevant GPCR conformations for naïve antibody selection; focus areas include cardiovascular, fibrotic, and rare diseases

Biotech Distilled coverage (4)

2026-09-29 UPDATE: Tectonic Therapeutic (TECX) - The Lottery Ticket Clears Its First Checkpoint 🔒 Paid
2026-08-07 UPDATE: Tectonic Therapeutic (TECX) - The IDMC Looked at 80% of the Data and Didn’t Blink 🔒 Paid
2026-06-10 UPDATE: Tectonic Therapeutic (TECX) - The Clock is Set
2026-06-09 Tectonic Therapeutic (TECX) — Scientific Deep Dive for TX45 (Relaxin/RXFP1) and TX2100 (APJ Antagonist)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.